| Developers: | Calidar |
| Date of the premiere of the system: | August 2025 |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
Content |
History
2025: Product Announcement
At the end of August 2025, the American startup Calidar introduced an innovative 4D mammography system that takes the accuracy of diagnosing malignant breast lesions to a new level. This imaging platform uses X-ray diffraction and artificial intelligence to conduct research at the molecular level.
As Calidar notes, despite decades of innovation in medical imaging, breast cancer and other soft tissue diseases are still difficult to detect in a non-invasive way with sufficient accuracy. Therefore, in the United States alone, about 1.5 million breast biopsies are performed annually: in 80% of these cases (approximately 1.2 million), neoplasms are ultimately diagnosed as benign. Such unnecessary procedures not only create discomfort for patients, but also cost more than $6 billion. In addition, excessive biopsies increase the burden on hospitals experiencing staff shortages. On the other hand, late diagnosis due to inconclusive imaging results leads to tens of thousands of women with breast cancer delaying treatment each year, reducing survival rates.
Calidar's first-of-its-kind 4D mammography system solves existing problems. The device measures how X-rays are scattered at the molecular level: this process is known as X-ray diffraction. This creates a unique structural signature that reflects the internal composition of breast tissue.
Unlike traditional X-rays, which are shape and density based, X-ray diffraction provides additional diagnostic information about what the tissue is made of. These specific data allow the classification of cancerous and benign formations with an accuracy four times that of traditional imaging systems.[1]
